Active Pharmaceutical Ingredients (APIs)

  • Vonoprazan

    • API Product   :   

      Vonoprazan

    • CEP   :   

    • WCC   :   

    • Therapeutic Use    :   

      Antiulcerative

    • Originator   :   

      Takeda Pharmaceutical

    • CAS No.    :   

      881681-00-1

    • Trade Name.   :   

      Takecab

    • Molecular Weight   :   

      345.39 g·mol−1

    • Molecular Formula   :   

      C17H16FN3O2S

    Application

    Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.

    General Description

    Vonoprazan (Vonoprazan fumarate or TAK-438) under brand name Takecab, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. The drug is approved in Japan for the treatment of acid-related diseases, including gastric ulcer, duodenal ulcer, reflux esophagitis and Adjunct to Helicobacter pylori eradication in the case of Helicobacter pylori gastritis.